Participated · Equity · Jan 2026

Founded in 2017 by Adnan Alshuaili, Issa Alshuaili and Awadh Al Shukaili, eMushrif offers an integrated hardware-and-software platform that brings real-time visibility, safety monitoring and route optimization to school bus fleets. The company’s AI- and IoT-enabled system serves more than 120,000 students across public and private schools in Oman and Kuwait, working closely with both government bodies and private operators. By combining vehicle-mounted sensors, student check-in hardware and cloud dashboards, eMushrif gives parents, schools and regulators up-to-the-minute data on bus location and student safety. In 2021, the company expanded its product footprint through the acquisition of Egypt-based transport tracking app Tareeqi. With fresh capital, eMushrif plans to scale into Saudi Arabia and the UAE while continuing to invest in product development and operational capabilities in its core markets. The firm positions itself within a multi-billion-dollar global market for student transportation safety and compliance technologies.

Participated · Series A · Jul 2024

44.01 develops mineralisation technology that accelerates the natural process of turning captured CO2 into stable rock, achieving permanent removal in less than twelve months. The company says its approach can be deployed where mafic and ultramafic rock formations exist, which are found on every continent, enabling global scalability. 44.01 has completed pilot projects in Oman and the UAE and won the Earthshot Prize in 2022; its Project Hajar was also named an XPRIZE Carbon Removal Top 20 Finalist. The business raised a $37M Series A to continue refining its technology, build commercial‑scale projects, and expand international deployment. The funding round signals investor confidence and will support commercialization and modular project rollouts as an alternative to conventional geological carbon storage. 44.01 is building a system to mineralize CO2 by accelerating the natural reaction between carbonated water and peridotite to produce calcite. Its approach uses engineered boreholes to maximize rock surface area and cyclic injection of highly carbonated water with no catalysts or toxic additives. The company is working the logistics side to minimize operational emissions, including a biodiesel supply line with Wakud and nighttime solar offset plans. A scientific committee including Peter Kelemen and Juerg Matter advises the effort, and 44.01 is partnering with Climeworks and other carbon‑capture companies to source CO2. The initial work is focused on the large exposed peridotite deposits on Oman's northern coast, with a possible first commercial site across the border in the UAE. The seed funding is intended to secure permits, studies and demonstration equipment; the company acknowledges the $5M is far short of building full commercial operations.

Participated · Series B · Jul 2023

Energy Dome develops a CO2-based thermo-mechanical long-duration energy storage system called the CO2 Battery. The standard frame is 20MW/200MWh and can supply energy to the grid for ten consecutive hours. The design is modular and standardized, intended to be replicated as a series of identical units to unlock cost reductions and accelerate bankability. Energy Dome says the CO2 Battery achieves high round-trip efficiency, has competitive capital expenditure versus lithium-ion, and does not rely on rare metals. Main components use existing supply chains, which the company expects will enable job creation in Europe. A commercial operation date for the first project in Sardinia, Italy, is expected in Q3 2024, and the deployment is supported by recent funding commitments. Energy Dome invented and develops the CO2 Battery™, a long‑duration energy storage system that uses carbon dioxide to store energy efficiently and cost‑effectively. The system is modular, site‑independent, and built from off‑the‑shelf components to enable scalable deployment. Energy Dome positions its technology to make solar and wind power dispatchable 24/7, removing intermittency and supporting grid decarbonization. The company offers customers Storage‑as‑a‑Service (fund, build, own, operate) and an OEM purchase option with performance guarantees. Energy Dome has a project pipeline exceeding nine GWh across utilities, independent power producers, and corporations on five continents. The company is executing a 20 MW, 200 MWh CO2 Battery™ project planned to be operational by the end of 2024 and has signed an MOU with Oman Investment Authority to explore collaboration in Oman. Energy Dome has developed a commercial CO2 Battery that stores renewable energy by compressing/evaporating CO2 (gas↔liquid) to generate and store heat for later power generation. The system’s core components include an inflatable CO2 gas holder plus steel and water; the company claims 75% round‑trip efficiency (AC‑AC, MV‑MV), no degradation over 30 years, and roughly half the cost of lithium batteries. Founded in 2020, the startup says it is working with utilities, independent power producers and corporates and has a qualified pipeline exceeding 9 GWh across the U.S., Europe, South America, India and Australia. Energy Dome reports the first unit is already in manufacture and expects two standard 20 MW / 200 MWh frames to be commercially operational by the end of 2024. The company is positioning the technology for global commercial scaling, with particular focus on the U.S. to leverage tax incentives. Its stated aims include proving performance to customers via financial guarantees and expanding business development and deployment capacity. Energy Dome invented the CO2 Battery, a long-duration energy storage (LDES) system designed to make solar and wind power dispatchable 24/7. The technology leverages the thermodynamic properties of carbon dioxide to store energy efficiently with a modular, site-independent footprint. CO2 Batteries are built from readily available, off-the-shelf components, enabling deployment via existing supply chains. The company says the system offers high-efficiency storage at competitive cost, addressing a gap in long-duration storage needed for grid decarbonization. Energy Dome plans to scale up deployment of its CO2 Batteries across global markets. The company is based in Milan and is pursuing commercialization and broader market adoption. Energy Dome develops a CO2 battery that stores energy by cycling CO2 between gas and liquid in a closed-loop system. The design uses an inflatable dome, compressors, thermal storage and liquid CO2 vessels to charge and discharge electricity. The company claims 75%–80% round-trip efficiency and projects an operational life around 25 years. It says lifecycle cost of storage will be about half that of similarly sized lithium-ion batteries. The system can hold up to 200 MWh and is optimized for 4–24 hour charge/discharge cycles for daily and intra-day cycling. Energy Dome plans to deploy its first commercially viable demonstration project in Sardinia, Italy and recently closed a funding round to support that effort.

Participated · Series C · Nov 2020

Congenica offers a clinical genomic analysis software and data platform that enables rapid interpretation of complex genomic data for hospitals, diagnostic laboratories, academic medical centres and pharmaceutical companies. Its software performs up to 20x faster than industry averages, delivers a 30% higher analytical yield and can reduce genomic interpretation costs by up to 95%. Born out of research from the Wellcome Sanger Institute and the NHS, Congenica is the exclusive Clinical Decision Support partner for the UK NHS Genomic Medicine Service and supports customers across 18 countries. The company plans to accelerate commercialization of rare and inherited cancer applications and expand its platform into somatic cancer, wellness and pharmaceutical collaborations. Product development priorities include integration with existing electronic health systems and fully automated interpretation capability, underpinned by expanded machine-learning capabilities. The company completed a $50m Series C in November 2020 to fund these initiatives. Congenica provides the Sapientia diagnostic decision‑support platform and associated clinical services that enable clinicians to interrogate the human genome to identify disease‑causing variants. The company is led by CEO Dr David Atkins and was recently awarded a multi‑year contract as the exclusive provider of Diagnostic Decision Support Services for the NHS Genomic Medicine Service. Congenica said it will use new funds to accelerate commercial scale‑up and further penetrate international markets, with an initial focus on the US and China. It also plans to develop an enhanced product platform that harnesses statistics and machine‑learning technology to augment clinicians’ diagnostic decision‑making. Following the latest raise, Congenica has increased its total funding to date to £26m ($33.5m). Congenica is a Cambridge, UK–based provider of clinical genome analysis technology centered on its Sapientia platform. Sapientia analyzes genome-scale DNA data to produce comprehensive diagnostic reports that facilitate clinical decision-making and inform R&D. Since its launch in 2014 the technology has been adopted across the UK, China, the US and other EU countries and has been validated by independent institutes and clinicians including Genomics England under the UK 100K Genomes Project. The company plans to use the £8m Series B to sustain the commercial roll-out of Sapientia by accelerating international growth and expanding customer support. It will also invest in further product development and innovation. The round included existing investors Cambridge Innovation Capital and Amadeus Capital Partners and new investor Parkwalk Advisors; Parkwalk's Alastair Kilgour will join the board. Congenica is led by CEO Tom Weaver, COO Dr Martin Dougherty and Chief Business Officer Dr Shikha O’Brien.

Participated · Series B · Jun 2020

Polares Medical SA is building MRace, a Posterior Leaflet Replacement (PLR) system intended to broaden transcatheter treatment options for patients with mitral regurgitation, especially those whose anatomy limits use of transcatheter edge-to-edge repair (TEER). More than 70 patients have now received the device, and one-year data show sustained safety and efficacy, validating the PLR concept. The company positions MRace to simplify procedures, cover a wider spectrum of mitral anatomies, and preserve future treatment pathways. Proceeds from its latest financing will fund further clinical studies across the United States, Europe, and Australia and support U.S. market expansion. Headquartered in Lausanne, Switzerland, with U.S. operations in Palo Alto, California, Polares is targeting one of structural heart’s largest markets with what investors view as a differentiated approach. The strong clinical momentum has helped the company close an oversubscribed Series C, providing additional runway for product development and regulatory progress.